{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-010895","form_type":"8-K","ticker":"RNXT","cik":"0001574094","company_name":"RenovoRx, Inc.","filed_at":"2025-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.842202+00:00","generated_at":"2026-05-21T04:58:07.961759+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"RenovoRx Q1 revenue ~$200K from RenovoCath sales; TIGeR-PaC trial 91 patients randomized","bullets":["Q1 2025 revenue of ~$200K from commercial RenovoCath sales, exceeding internal expectations; gross profit $103K.","Cash $14.6M as of Mar 31, 2025, up from $7.2M at Dec 31, 2024; funds commercial scale-up and trial completion.","Phase III TIGeR-PaC trial: 91 patients randomized, 56 events (second interim analysis triggered); DMC review expected Q3 2025.","Net loss $2.4M vs $1.1M in Q1 2024 due to higher operating costs and lower warrant liability gain.","Management and Board purchased ~143K shares; new U.S. patent issued for TAMP platform (19 patents total)."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-010895","json":"https://secwatch.observer/filing/0001641172-25-010895.json","markdown":"https://secwatch.observer/filing/0001641172-25-010895.md","text":"https://secwatch.observer/filing/0001641172-25-010895.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1574094/000164117225010895/0001641172-25-010895-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1574094/000164117225010895/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T04:58:07.961759+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}